GlaxoSmithKline Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . GlaxoSmithKline PLC ADR
GSK Stock  USD 49.02  0.61  1.23%   
Analyzing historical trends in various income statement and balance sheet accounts from GlaxoSmithKline PLC's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting GlaxoSmithKline PLC's valuation are summarized below:
Gross Profit
23.3 B
Profit Margin
0.1708
Market Capitalization
99.2 B
Enterprise Value Revenue
2.746
Revenue
32.2 B
There are currently one hundred twenty fundamental trends for GlaxoSmithKline PLC ADR that can be evaluated and compared over time across competitors. We recommend to confirm GlaxoSmithKline PLC's regular fundamental drivers against the all of the trends between 2010 and 2026. The value of Market Cap is estimated to slide to about 40.8 B. The Enterprise Value is projected to slide to about 44.2 B

GlaxoSmithKline PLC Total Revenue

19.77 Billion

Check GlaxoSmithKline PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlaxoSmithKline PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.1 B, Interest Expense of 495.6 M or Total Revenue of 19.8 B, as well as many indicators such as Price To Sales Ratio of 1.91, Dividend Yield of 0.0394 or PTB Ratio of 4.39. GlaxoSmithKline financial statements analysis is a perfect complement when working with GlaxoSmithKline PLC Valuation or Volatility modules.
  
Build AI portfolio with GlaxoSmithKline Stock
Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.

GlaxoSmithKline PLC Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets36.5 B68.4 B59.8 B
Slightly volatile
Short and Long Term Debt Total12.1 B19.5 B20.7 B
Slightly volatile
Other Current Liabilities18.3 B17.5 B11.1 B
Slightly volatile
Total Current Liabilities26.2 B25 B20.9 B
Slightly volatile
Property Plant And Equipment Net7.6 B11.6 B10.3 B
Slightly volatile
Net Debt9.2 B15.3 B16.2 B
Slightly volatile
Accounts Payable3.3 B4 B5.8 B
Very volatile
Cash2.9 B4.2 B4.5 B
Very volatile
Non Current Assets Total51.3 B48.8 B43.8 B
Slightly volatile
Cash And Short Term Investments4.1 B4.3 B5.1 B
Slightly volatile
Net Receivables4.6 B6.9 B6.2 B
Slightly volatile
Common Stock Shares Outstanding1.7 B1.9 B1.9 B
Pretty Stable
Short Term Investments18 M18.9 M508.9 M
Pretty Stable
Liabilities And Stockholders Equity36.5 B68.4 B59.8 B
Slightly volatile
Non Current Liabilities Total15.8 B28.4 B28.3 B
Slightly volatile
Inventory3.3 B6.5 B5.2 B
Slightly volatile
Other Current Assets1.9 B1.9 B2.4 B
Pretty Stable
Other Stockholder Equity5.5 B5.2 B4 B
Slightly volatile
Total Liabilities28.2 B53.3 B48.3 B
Slightly volatile
Property Plant And Equipment Gross24.8 B23.6 B12.3 B
Slightly volatile
Total Current Assets12.8 B19.5 B17.6 B
Slightly volatile
Capital Stock1.3 B1.6 B1.3 B
Slightly volatile
Short Term Debt2.4 B2.7 B3.5 B
Pretty Stable
Common Stock1.3 B1.6 B1.4 B
Slightly volatile
Intangible Assets10.7 B17.8 B18 B
Slightly volatile
Other Liabilities14.2 B11.7 B16.9 B
Very volatile
Long Term Debt17.4 B15.8 B17.9 B
Very volatile
Good Will5.9 B8 B7 B
Slightly volatile
Property Plant Equipment9.6 B9.1 B11.2 B
Slightly volatile
Other Assets5.6 B8.8 B5.5 B
Slightly volatile
Long Term Investments77.6 B73.9 B37.6 B
Slightly volatile
Short and Long Term Debt1.9 B2 B7.1 B
Slightly volatile
Additional Paid In Capital3.4 B4 B3.1 B
Slightly volatile
Long Term Debt Total19.7 B16.8 B17.2 B
Slightly volatile
Capital Surpluse3.5 B4 B3.2 B
Slightly volatile
Net Invested Capital21.4 B26.6 B22.4 B
Slightly volatile
Cash And Equivalents2.3 B2.5 B3.4 B
Slightly volatile

GlaxoSmithKline PLC Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.1 B2.9 B1.9 B
Slightly volatile
Interest Expense495.6 M756.2 M708.6 M
Slightly volatile
Total Revenue19.8 B36.1 B26.3 B
Slightly volatile
Gross Profit14.5 B25.7 B18 B
Slightly volatile
Other Operating Expenses33 B31.5 B22 B
Slightly volatile
Operating Income4.7 B4.6 B5.5 B
Very volatile
EBIT4.9 B4.7 B5.6 B
Very volatile
Research Development7.7 B7.4 B4.6 B
Slightly volatile
EBITDA6.1 B7.7 B7.4 B
Very volatile
Total Operating Expenses22.1 B21.1 B13.3 B
Slightly volatile
Income Before Tax4.7 B4 B4.9 B
Very volatile
Net Income3.7 B3 B4.5 B
Pretty Stable
Income Tax Expense1.1 B604.9 M912.3 M
Slightly volatile
Selling General Administrative9.6 B12.7 B9 B
Slightly volatile
Cost Of Revenue7.5 B10.4 B8.5 B
Slightly volatile
Net Income Applicable To Common Shares2.2 B2.3 B5.4 B
Slightly volatile
Selling And Marketing Expenses317.2 M333.9 M1.1 B
Slightly volatile
Net Income From Continuing Ops2.5 B2.7 B9.1 B
Pretty Stable
Tax Provision644.5 M473.4 M1.2 B
Slightly volatile
Interest Income51.3 M54 M429.1 M
Slightly volatile
Reconciled Depreciation2.4 B2.9 B2.1 B
Slightly volatile

GlaxoSmithKline PLC Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Free Cash Flow3.5 B4.1 B4.3 B
Slightly volatile
Begin Period Cash Flow2.3 B3.3 B4.1 B
Pretty Stable
Depreciation3.1 B2.9 B2 B
Slightly volatile
Capital Expenditures3.6 B3.4 B2.1 B
Slightly volatile
Total Cash From Operating Activities5 B7.5 B6.3 B
Slightly volatile
Net Income4.6 B3.4 B4.4 B
Pretty Stable
End Period Cash Flow2.2 B3.9 B4 B
Pretty Stable
Dividends Paid3.4 B2.8 B3.5 B
Very volatile
Stock Based Compensation338 M395.6 M321.9 M
Slightly volatile
Change To Liabilities596.5 M568.1 M296.3 M
Slightly volatile
Issuance Of Capital Stock26.3 M18 M51 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.912.012.6384
Slightly volatile
Dividend Yield0.03940.04010.0583
Pretty Stable
Days Sales Outstanding86.3492.7878.915
Slightly volatile
Book Value Per Share3.032.892.6121
Slightly volatile
Free Cash Flow Yield0.04320.05860.0703
Pretty Stable
Operating Cash Flow Per Share0.881.451.5491
Slightly volatile
Stock Based Compensation To Revenue0.00860.00990.0108
Pretty Stable
Capex To Depreciation1.471.341.2514
Slightly volatile
EV To Sales2.372.53.1551
Slightly volatile
Free Cash Flow Per Share0.60.791.0378
Pretty Stable
ROIC0.230.140.151
Slightly volatile
Inventory Turnover2.061.921.8081
Very volatile
Net Income Per Share0.640.571.1313
Pretty Stable
Days Of Inventory On Hand160197205
Pretty Stable
Payables Turnover3.963.152.6433
Slightly volatile
Sales General And Administrative To Revenue0.460.410.3774
Pretty Stable
Research And Ddevelopement To Revenue0.110.160.1384
Slightly volatile
Capex To Revenue0.08230.110.0829
Very volatile
Cash Per Share0.690.861.1834
Very volatile
POCF Ratio9.159.6312.3485
Slightly volatile
Interest Coverage9.6110.1113.8073
Slightly volatile
Payout Ratio0.820.851.123
Very volatile
Capex To Operating Cash Flow0.480.520.3978
Pretty Stable
PFCF Ratio16.7917.67253
Slightly volatile
Days Payables Outstanding175153187
Slightly volatile
Income Quality1.022.01.7707
Very volatile
EV To Operating Cash Flow11.3711.9614.7638
Slightly volatile
PE Ratio27.8524.5220.5212
Pretty Stable
Return On Tangible Assets0.07610.08010.1423
Pretty Stable
EV To Free Cash Flow20.8521.95263
Slightly volatile
Earnings Yield0.04790.04220.0783
Very volatile
Intangibles To Total Assets0.180.340.3555
Slightly volatile
Net Debt To EBITDA0.941.791.9051
Pretty Stable
Current Ratio1.490.91.0247
Slightly volatile
Receivables Turnover3.874.074.6864
Slightly volatile
Graham Number3.986.217.0086
Slightly volatile
Capex Per Share0.690.660.5353
Slightly volatile
Revenue Per Share3.516.936.6832
Slightly volatile
Interest Debt Per Share2.13.934.8716
Pretty Stable
Debt To Assets0.220.260.3291
Pretty Stable
Enterprise Value Over EBITDA16.1511.7511.253
Pretty Stable
Short Term Coverage Ratios2.272.512.0115
Slightly volatile
Price Earnings Ratio27.8524.5220.5212
Pretty Stable
Operating Cycle173269260
Slightly volatile
Days Of Payables Outstanding175153187
Slightly volatile
Dividend Payout Ratio0.820.851.123
Very volatile
Price To Operating Cash Flows Ratio9.159.6312.3485
Slightly volatile
Price To Free Cash Flows Ratio16.7917.67253
Slightly volatile
Pretax Profit Margin0.120.130.2005
Slightly volatile
Ebt Per Ebit1.030.710.8595
Pretty Stable
Operating Profit Margin0.320.210.2503
Slightly volatile
Effective Tax Rate0.290.170.2025
Slightly volatile
Long Term Debt To Capitalization0.370.450.622
Pretty Stable
Total Debt To Capitalization0.420.50.6654
Pretty Stable
Return On Capital Employed0.160.170.2031
Slightly volatile
Ebit Per Revenue0.320.210.2503
Slightly volatile
Quick Ratio1.180.60.7402
Slightly volatile
Dividend Paid And Capex Coverage Ratio0.841.091.1233
Pretty Stable
Net Income Per E B T0.60.670.8527
Pretty Stable
Cash Ratio0.170.160.2328
Slightly volatile
Cash Conversion Cycle84.3149134
Pretty Stable
Operating Cash Flow Sales Ratio0.160.190.221
Very volatile
Days Of Inventory Outstanding160197205
Pretty Stable
Days Of Sales Outstanding86.3492.7878.915
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.450.490.5987
Pretty Stable
Cash Flow Coverage Ratios0.570.440.3641
Pretty Stable
Fixed Asset Turnover2.12.82.792
Pretty Stable
Capital Expenditure Coverage Ratio2.661.982.9965
Pretty Stable
Price Cash Flow Ratio9.159.6312.3485
Slightly volatile
Enterprise Value Multiple16.1511.7511.253
Pretty Stable
Debt Ratio0.220.260.3291
Pretty Stable
Cash Flow To Debt Ratio0.570.440.3641
Pretty Stable
Price Sales Ratio1.912.012.6384
Slightly volatile
Return On Assets0.04730.04980.0927
Slightly volatile
Asset Turnover0.780.610.5504
Pretty Stable
Net Profit Margin0.08970.09440.1731
Pretty Stable
Gross Profit Margin0.790.80.7029
Very volatile

GlaxoSmithKline PLC Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap40.8 B46.8 B49.3 B
Pretty Stable
Enterprise Value44.2 B61.1 B63.1 B
Pretty Stable

GlaxoSmithKline Fundamental Market Drivers

Forward Price Earnings9.5694
Cash And Short Term Investments3.7 B

GlaxoSmithKline Upcoming Events

31st of January 2024
Upcoming Quarterly Report
View
24th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
31st of January 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About GlaxoSmithKline PLC Financial Statements

GlaxoSmithKline PLC investors utilize fundamental indicators, such as revenue or net income, to predict how GlaxoSmithKline Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue325.5 M341.7 M
Total Revenue36.1 B19.8 B
Cost Of Revenue10.4 B7.5 B
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.41  0.46 
Research And Ddevelopement To Revenue 0.16  0.11 
Capex To Revenue 0.11  0.08 
Revenue Per Share 6.93  3.51 
Ebit Per Revenue 0.21  0.32 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:
How To Invest In GlaxoSmithKline
Details
Is GlaxoSmithKline Stock a good investment?
Details
What is GlaxoSmithKline PLC's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.232
Dividend Share
0.64
Earnings Share
3.58
Revenue Per Share
15.82
Quarterly Revenue Growth
0.067
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY